<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04807894</url>
  </required_header>
  <id_info>
    <org_study_id>702576</org_study_id>
    <nct_id>NCT04807894</nct_id>
  </id_info>
  <brief_title>Prevention of Recurrent UTI Using Vaginal Testosterone Versus Placebo Placebo</brief_title>
  <acronym>PIVoT</acronym>
  <official_title>Prevention of Recurrent Urinary Tract Infection Using Vaginal Testosterone Versus Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maimonides Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Urological Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maimonides Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Women over the age of 60 years have an estimated 10 to 15 % risk of recurrent urinary tract&#xD;
      infections (UTI). This is believed to be due to hormonally induced changes in the vaginal&#xD;
      flora associated with menopause. After menopause, there is a chemical changes in the vagina&#xD;
      that may predispose to bacterial infections.&#xD;
&#xD;
      The role of vaginal estrogen creams to restore vaginal atrophy and prevent urinary tract&#xD;
      infections has been well characterized. Vaginal testosterone (VT) application use in&#xD;
      postmenopausal breast cancer patients on aromatase inhibitors have been shown to improve&#xD;
      vaginal pH, vaginal atrophy symptom scores, dyspareunia, and vaginal dryness. Although&#xD;
      testosterone has been used to improve sexual function in postmenopausal women, the effects of&#xD;
      VT on vaginal flora and recurrent UTIs are unknown.&#xD;
&#xD;
      The purpose of this study is to determine whether topically applied vaginal testosterone&#xD;
      cream is more effective than placebo in reducing the incidence of urinary tract infections in&#xD;
      postmenopausal women with recurrent urinary tract infections and to ascertain the effects of&#xD;
      topical estrogen on the vaginal pH and flora.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:&#xD;
&#xD;
      Women over the age of 60 years have an estimated 10 to 15 % risk of recurrent urinary tract&#xD;
      infections (UTI). This is believed to be due to hormonally induced changes in the vaginal&#xD;
      flora associated with menopause. After menopause, there is a chemical changes in the vagina&#xD;
      that may predispose to bacterial infections.&#xD;
&#xD;
      The role of vaginal estrogen creams to restore vaginal atrophy and prevent urinary tract&#xD;
      infections has been well characterized. Vaginal testosterone (VT) application use in&#xD;
      postmenopausal breast cancer patients on aromatase inhibitors have been shown to improve&#xD;
      vaginal pH, vaginal atrophy symptom scores, dyspareunia, and vaginal dryness. Although&#xD;
      testosterone has been used to improve sexual function in postmenopausal women, the effects of&#xD;
      VT on vaginal flora and recurrent UTIs are unknown.&#xD;
&#xD;
      The purpose of this study is to determine whether topically applied vaginal testosterone&#xD;
      cream is more effective than placebo in reducing the incidence of urinary tract infections in&#xD;
      postmenopausal women with recurrent urinary tract infections and to ascertain the effects of&#xD;
      topical estrogen on the vaginal pH and flora.&#xD;
&#xD;
      Methods:&#xD;
&#xD;
      This will be a multi-center randomized, double- blind placebo-controlled study. Participating&#xD;
      clinic sites include Maimonides Medical Center and Northwell Health. Subjects will be one&#xD;
      hundred postmenopausal women presenting to a gynecology, urogynecology or female urology&#xD;
      clinic with a history of three or more microbiologically confirmed symptomatic episodes of&#xD;
      urinary tract infection during the either the previous year or two or more within six months.&#xD;
&#xD;
      Patients will randomly assigned to one of two regimens: one group will receive VT cream to be&#xD;
      used once each night for two weeks followed by twice-weekly applications for eight months,&#xD;
      and the other group will receive a placebo cream to be used in the same manner. Demographic&#xD;
      data, vaginal exam including vaginal swab to assess vaginal flora, vaginal pH measurement and&#xD;
      vaginal atrophy index measurement will be collected at the initial study visit, again at a&#xD;
      study visit at 4.5 months and another at 9 months.&#xD;
&#xD;
      Anticipated Results and Conclusion:&#xD;
&#xD;
      It is anticipated that vaginal testosterone cream will reduce the incidence of urinary tract&#xD;
      infections in postmenopausal women when compared to placebo. It is expected that vaginal&#xD;
      testosterone will improve vaginal atrophy and flora, thus, decreasing the frequency of&#xD;
      urinary tract infections. Future aims of the study will focus on immune-dynamics associated&#xD;
      with vaginal testosterone administration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2020</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess whether topical vaginal testosterone cream is more effective than placebo in reducing the incidence of urinary tract infections in postmenopausal women with recurrent urinary tract infections.</measure>
    <time_frame>1 month</time_frame>
    <description>Patients will receive months phone calls to assess for symptoms of UTI and urine will be collected in study visits at 1 month to check for presence of UTI.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess whether topical vaginal testosterone cream is more effective than placebo in reducing the incidence of urinary tract infections in postmenopausal women with recurrent urinary tract infections.</measure>
    <time_frame>4.5 months</time_frame>
    <description>Patients will receive months phone calls to assess for symptoms of UTI and urine will be collected in study visits at 4.5 months to check for presence of UTI.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess whether topical vaginal testosterone cream is more effective than placebo in reducing the incidence of urinary tract infections in postmenopausal women with recurrent urinary tract infections.</measure>
    <time_frame>9 months</time_frame>
    <description>Patients will receive months phone calls to assess for symptoms of UTI and urine will be collected in study visits at 9 months to check for presence of UTI.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To determine whether topically applied vaginal testosterone cream is more effective than placebo cream in changing vaginal flora and pH in postmenopausal women with recurrent urinary tract infections.</measure>
    <time_frame>1 month</time_frame>
    <description>The vaginal pH, vaginal atrophy score, and vaginal swabs for participants will be collected at 1 month to assess whether there is improvement in pH and vaginal atrophy scores as well as normalization of vaginal flora.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To determine whether topically applied vaginal testosterone cream is more effective than placebo cream in changing vaginal flora and pH in postmenopausal women with recurrent urinary tract infections.</measure>
    <time_frame>4.5 months</time_frame>
    <description>The vaginal pH, vaginal atrophy score, and vaginal swabs for participants will be collected at 4.5 months to assess whether there is improvement in pH and vaginal atrophy scores as well as normalization of vaginal flora.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To determine whether topically applied vaginal testosterone cream is more effective than placebo cream in changing vaginal flora and pH in postmenopausal women with recurrent urinary tract infections.</measure>
    <time_frame>9 months</time_frame>
    <description>The vaginal pH, vaginal atrophy score, and vaginal swabs for participants will be collected at 9 months to assess whether there is improvement in pH and vaginal atrophy scores as well as normalization of vaginal flora.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Recurrent Urinary Tract Infection</condition>
  <condition>Vaginal Atrophy</condition>
  <condition>Postmenopausal Disorder</condition>
  <arm_group>
    <arm_group_label>Vaginal Testosterone Cream Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women enrolled in this arm will receive vaginal testosterone cream to be applied once each night for two weeks followed by twice-weekly applications for a total duration of nine months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaginal Placebo Cream Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Women enrolled in this arm will receive vaginal placebo cream to be applied once each night for two weeks followed by twice-weekly applications for a total duration of nine months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vaginal Cream with Applicator</intervention_name>
    <description>Vaginal testosterone 300-Î¼g dose will be compounded with 13.5 mg of testosterone propionate in 0.45 mL of polysorbate National Formulary liquid and sufficient emollient cream base to make 45 g total. A calibrated vaginal applicator will be supplied to measure out doses of 1 g each. All study medications will be compounded by a single pharmacy so as to avoid variation in compounding between pharmacies and allow for control of compounding. Randomization will be conducted by the compounding pharmacy to allow for double-blinding of patients and clinicians.</description>
    <arm_group_label>Vaginal Placebo Cream Arm</arm_group_label>
    <arm_group_label>Vaginal Testosterone Cream Arm</arm_group_label>
    <other_name>Testosterone Cream</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  60-90 yo Female&#xD;
&#xD;
          -  Postmenopausal&#xD;
&#xD;
          -  Recurrent UTIs (three or more culture confirmed symptomatic episodes of UTI or two or&#xD;
             more in the past 6 months).&#xD;
&#xD;
          -  English Proficiency&#xD;
&#xD;
          -  Unable or unwilling to use topical estrogen.&#xD;
&#xD;
          -  Patients with history of or current endometrial or breast cancer and current aromatase&#xD;
             inhibitor therapy may also be included in study.&#xD;
&#xD;
          -  Patient on oral estrogen therapy may be included.&#xD;
&#xD;
          -  Patient with slings, prior vaginal surgery or pessary may be included.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current UTI/ Dipstick and culture positive (&gt; trace leukocytes or nitrites)&#xD;
&#xD;
          -  Antibiotic (vaginal or oral) use in the last 4 weeks&#xD;
&#xD;
          -  Current sexually transmitted infection&#xD;
&#xD;
          -  Chronic Foley catheter use or chronic ureteral stent placement.&#xD;
&#xD;
          -  Vaginal probiotic use in the last 4 weeks&#xD;
&#xD;
          -  Patient currently using vaginal estrogen.&#xD;
&#xD;
          -  Post-void Residual Volume &gt;150 mL or current diagnosis of urinary retention&#xD;
&#xD;
          -  Non-evaluated hematuria (&gt; trace on dipstick, microscopic, gross)&#xD;
&#xD;
          -  Unable to complete study tasks or comply with follow up.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Study is aimed at postmenopausal women with history of recurrent UTIs.</gender_description>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alison Polland, MD</last_name>
    <phone>(718) 283-7770</phone>
    <email>apolland@maimonidesmed.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mariela Martinez, MD</last_name>
    <email>mmrivera@maimonidesmed.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Maimonides Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alison Polland, MD</last_name>
      <phone>718-283-7770</phone>
      <email>apolland@maimonidesmed.org</email>
    </contact>
    <investigator>
      <last_name>Alison Polland, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>October 19, 2020</study_first_submitted>
  <study_first_submitted_qc>March 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2021</study_first_posted>
  <last_update_submitted>March 18, 2021</last_update_submitted>
  <last_update_submitted_qc>March 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>urinary tract infections,</keyword>
  <keyword>postmenopausal women</keyword>
  <keyword>vaginal atrophy,</keyword>
  <keyword>vaginal flora</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

